1. Introduction

Cross-border tele-genetics services refer to the provision of genetic counselling, genetic testing, genomic interpretation, hereditary disease assessment and related healthcare services through digital communication platforms where the patient, healthcare professional, genetic laboratory or service provider is situated in different countries.

These services allow individuals to obtain genetic healthcare without physically visiting a geneticist or laboratory. They include:

Online genetic counselling and interpretation of genetic test results.

Remote diagnosis of inherited disorders.

Direct-to-consumer (DTC) genetic testing.

Cross-border transmission of DNA samples.

Remote prenatal and reproductive genetic counselling.

Online assessment of hereditary cancer risks.

Pharmacogenomic testing and personalised medicine.

International sharing of genomic databases.

AI-assisted genetic risk prediction.

Remote counselling concerning embryo and reproductive genetics.

The central legal question is whether a genetic service provider established in one country can lawfully collect genetic information, analyse DNA, communicate medical advice and provide clinical recommendations to a patient located in another country.

The answer depends on several intersecting areas of law: medical licensing, telemedicine regulation, informed consent, genetic-data protection, laboratory accreditation, bioethics, consumer protection, medical negligence and international private law.

There is no single universal international licence for tele-genetics. A provider may comply with the law of its home country but still violate the regulatory requirements of the patient's country.

2. Meaning and Nature of Cross-Border Tele-Genetics

Tele-genetics is a specialised branch of telemedicine that combines genetic science with remote healthcare delivery.

Its distinctive feature is that genetic information is particularly sensitive and may reveal information about not only the individual tested but also biological relatives.

For example:

A patient in India sends a saliva sample to a laboratory in the United States.

The laboratory analyses the patient's genetic material.

A genetic counsellor located in the United Kingdom interprets the results.

An online platform communicates the findings to the patient in India.

This apparently simple transaction may involve four separate legal jurisdictions.

Illustration: Cross-border tele-genetics transaction

Patient

India – genetic sample and consent

Digital transmission / biological sample transfer

Foreign genetic laboratory

United States – DNA analysis

Genomic results and interpretation

Genetic counsellor

United Kingdom – remote counselling

Patient receives genetic advice

Clinical and legal consequences in India

Each participant may have different legal responsibilities. The patient's location, the professional's location, the laboratory's location and the location where data is processed can all be legally relevant.

3. Legal Framework in India

India is particularly important in cross-border tele-genetics because the service may constitute both a medical consultation and the processing or transfer of sensitive personal information.

A. Information Technology Act, 2000

The Information Technology Act, 2000 provides a foundational legal framework for electronic records, electronic transactions and certain forms of cyber liability.

Relevant provisions include:

Section 43A: Historically provided compensation for failure by a body corporate to maintain reasonable security practices concerning sensitive personal data. Its present operation must be assessed in light of the Digital Personal Data Protection Act, 2023 and subsequent commencement notifications.

Section 66: Addresses specified computer-related offences.

Section 72: Addresses breach of confidentiality and privacy by persons obtaining access under powers conferred by the Act.

Section 72A: Addresses disclosure of information in breach of a lawful contract, subject to its statutory requirements.

A tele-genetics provider must ensure that genetic reports, electronic prescriptions and patient communications are protected against unauthorised access and disclosure.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 (DPDP Act) establishes India's framework for processing digital personal data.

Its relevance to tele-genetics includes:

Lawful processing and consent requirements.

Notice to individuals regarding data processing.

Duties of data fiduciaries.

Reasonable security safeguards.

Breach notification obligations under the applicable framework.

Rights of data principals.

Cross-border transfers under Section 16, subject to restrictions notified by the Central Government.

Genetic information is not separately classified as a special category in the DPDP Act in the manner adopted by the EU GDPR. Nevertheless, it is personal data when linked or reasonably identifiable to an individual and requires appropriate protection.

The applicable commencement notifications and rules must be checked for the relevant transaction date.

C. Telemedicine Practice Guidelines, 2020

India's Telemedicine Practice Guidelines, 2020, issued by the Board of Governors in supersession of the Medical Council of India, recognise remote medical consultations by registered medical practitioners.

Their importance for tele-genetics includes:

Verification of the patient's identity.

Identification of the registered medical practitioner.

Appropriate patient consent.

Maintenance of medical records.

Proper documentation of prescriptions.

Compliance with professional standards.

Recognition of circumstances in which physical examination or referral is necessary.

A foreign genetic counsellor cannot automatically assume that registration in another country authorises independent medical practice in India.

D. Clinical Establishments and laboratory regulation

Where applicable, the Clinical Establishments (Registration and Regulation) Act, 2010, and relevant state legislation may regulate establishments providing diagnostic and clinical services.

A foreign laboratory serving Indian patients must also consider applicable Indian rules governing importation, biological samples, diagnostic products and laboratory operations.

E. Pre-Conception and Pre-Natal Diagnostic Techniques Act, 1994

The PCPNDT Act is particularly relevant where tele-genetics involves prenatal genetic testing or sex determination.

The Act regulates prenatal diagnostic techniques and prohibits their misuse for sex selection.

Important provisions include:

Section 3: Regulation of genetic counselling centres, genetic laboratories and genetic clinics.

Section 3A: Prohibition of sex selection.

Section 4: Regulation of prenatal diagnostic techniques.

Section 5: Written consent and communication of test results.

Section 6: Prohibition of determination of sex.

Section 23: Penalties for specified contraventions.

A cross-border digital arrangement cannot be used to circumvent India's prohibitions on sex selection and unlawful prenatal diagnostic practices.

4. International Legal Framework

A. European Union: General Data Protection Regulation (GDPR)

The EU GDPR, Regulation (EU) 2016/679, provides one of the most significant legal frameworks for cross-border genetic-data processing.

Genetic information receives special protection under Article 9.

Important provisions include:

Under Article 9, genetic data generally cannot be processed unless a specified exception applies, such as explicit consent or an applicable healthcare or research provision with the required safeguards.

Cross-border implications:

A European genetic-testing company providing services to an individual in India may remain subject to GDPR where its activities fall within Article 3, particularly when it offers goods or services to individuals in the EU or monitors their behaviour there.

Conversely, an Indian tele-genetics provider processing genetic data of EU residents may become subject to GDPR even without a physical establishment in Europe.

International transfers from the EU must satisfy Chapter V requirements, including adequacy decisions, appropriate safeguards or applicable derogations.

B. United States: Genetic Information and Health Regulation

The United States regulates genetic services through several overlapping legal frameworks.

1. Genetic Information Nondiscrimination Act, 2008 (GINA)

GINA prohibits specified forms of genetic discrimination.

It primarily protects individuals against genetic discrimination in:

Health insurance.

Employment.

However, it does not generally prohibit genetic discrimination in life insurance, disability insurance or long-term-care insurance.

2. Health Insurance Portability and Accountability Act (HIPAA)

HIPAA protects individually identifiable health information held by covered entities and business associates.

Genetic information may qualify as protected health information.

However, an independent direct-to-consumer genetic testing company is not automatically covered by HIPAA merely because it handles genetic information.

3. Clinical Laboratory Improvement Amendments (CLIA)

CLIA regulates laboratories performing human diagnostic testing within its scope in the United States.

A laboratory conducting genetic tests for foreign patients must determine whether its activities fall within applicable CLIA requirements and any additional state requirements.

4. Food and Drug Administration (FDA)

The FDA regulates relevant genetic testing products and medical devices according to their intended use and applicable statutory requirements.

Its oversight is particularly important where genetic tests are marketed for diagnosing disease, predicting medical conditions or guiding treatment.

The FDA's authorisation of particular direct-to-consumer tests does not amount to blanket approval of all commercial genetic testing services.

FDA

C. United Kingdom: Genetic Counselling and Data Protection

The United Kingdom regulates tele-genetics through overlapping laws and professional standards.

Important frameworks include:

UK GDPR.

Data Protection Act 2018.

Human Tissue Act 2004.

Human Fertilisation and Embryology Act 1990, as amended.

Human Medicines Regulations 2012, where applicable.

Professional standards of the General Medical Council.

Standards of the relevant genetic counselling and laboratory professional bodies.

A provider offering remote genetic counselling must distinguish between general educational information and regulated clinical diagnosis or treatment.

D. International Bioethics Framework

The following international instruments provide important ethical and interpretative guidance:

UNESCO Universal Declaration on the Human Genome and Human Rights, 1997.

UNESCO International Declaration on Human Genetic Data, 2003.

UNESCO Universal Declaration on Bioethics and Human Rights, 2005.

Convention on Human Rights and Biomedicine (Oviedo Convention), 1997, for its parties.

Council of Europe's data protection framework, Convention 108 and its modernised form.

These instruments address dignity, consent, confidentiality, discrimination, genetic identity and the responsible use of genetic information.

They do not create one universally enforceable licensing system for international tele-genetics providers.

5. Cross-Border Medical Licensing and Professional Jurisdiction

One of the most difficult legal questions is determining which country's medical licence is necessary.

Consider the following situation:

An Indian patient consults a genetic physician located in Canada through a video consultation.

The physician may be legally authorised to practise in Canada. However, that does not automatically establish that the physician is authorised to provide clinical medical services to patients located in India.

The following questions arise:

Is the foreign professional providing medical diagnosis or merely educational information?

Does the service constitute practising medicine in the patient's country?

Does the patient's country recognise foreign professional qualifications?

Is local registration mandatory?

Can the foreign professional prescribe medication?

Who is responsible for follow-up and emergency referrals?

Important Indian position: The 2020 Indian Telemedicine Practice Guidelines expressly address consultations by registered medical practitioners within India and exclude teleconsultations outside India's jurisdiction. They should not be treated as a universal authorisation for foreign doctors to practise in India.

Ministry of Health and Family Welfare+1

A foreign specialist who provides a second opinion to an Indian registered medical practitioner presents a different legal situation from one who independently diagnoses and treats the Indian patient.

The distinction between doctor-to-doctor consultation and direct doctor-to-patient treatment is important.

6. Informed Consent in Cross-Border Tele-Genetics

Informed consent is one of the central requirements of lawful genetic healthcare.

Ordinary medical consent may not be sufficient because genetic testing can disclose information about:

Hereditary diseases.

Cancer susceptibility.

Carrier status.

Biological parentage.

Familial relationships.

Ancestry.

Reproductive risks.

Future health risks.

A legally adequate consent procedure should explain:

A. Purpose of testing

The patient must understand whether the testing is intended for diagnosis, screening, research, reproductive planning or ancestry analysis.

B. Scope of testing

The provider should disclose whether the test examines a single gene, a gene panel, whole-exome sequencing or whole-genome sequencing.

C. Secondary findings

The patient should be informed about the possibility of discovering unrelated medically significant genetic information.

D. Family implications

Genetic findings may reveal risks affecting biological relatives who have not personally consented to the test.

E. International transfer

The patient should receive understandable information about the countries where the biological sample, genetic data and medical reports may be processed or stored.

F. Future research

The provider must distinguish clinical testing consent from consent for research, commercial reuse or unrelated secondary processing.

G. Data retention and destruction

The patient should be informed about retention periods, sample destruction procedures and circumstances in which deletion may be restricted by law.

H. Withdrawal of consent

Withdrawal should be explained, including its limitations once data has been lawfully processed, anonymised or incorporated into research.

A click on a general website's terms and conditions should not automatically be treated as sufficient informed consent for every aspect of genomic testing.

7. Cross-Border Transfer of DNA Samples

Cross-border tele-genetics is not limited to the electronic transmission of data.

Many genetic services require the physical transportation of:

Blood samples.

Saliva specimens.

Buccal swabs.

Tissue samples.

Embryonic cells.

Extracted DNA.

Other biological materials.

The transfer may trigger several regulatory requirements.

Principal legal issues

1. Export permission

The exporting country may regulate the removal of biological material for foreign testing or research.

2. Import permission

The receiving country may impose customs, biosafety, health and laboratory requirements.

3. Human biological material

Certain samples may be subject to specific human-tissue legislation.

4. Dangerous goods and infectious materials

Where specimens present a biological hazard, applicable packaging, classification and transport rules must be followed.

5. Research versus clinical use

A sample exported for clinical diagnosis should not automatically be used for unrelated commercial or research purposes.

6. Material Transfer Agreements

An MTA can specify:

Permitted uses.

Ownership and custody.

Storage duration.

Transfer restrictions.

Secondary research.

Publication rights.

Destruction or return.

Responsibility for sample loss.

For Indian transfers involving biological resources, the Biological Diversity Act, 2002, as amended, may also require consideration where the relevant material falls within its scope. It should not, however, be assumed that every human DNA sample automatically constitutes a regulated biological resource under that Act.

8. Genetic Privacy and Confidentiality

Genetic privacy is more complicated than ordinary medical confidentiality.

A genetic report may identify an individual indirectly through family relationships, even where the patient's name is removed.

For example, a foreign genetic database may combine an individual's DNA profile with publicly accessible family-tree information and identify biological relatives.

This raises questions concerning:

Re-identification.

Unauthorised genetic profiling.

Commercial exploitation.

Disclosure to employers.

Insurance discrimination.

Government access.

Cross-border surveillance.

Familial privacy.

A provider must not assume that removing names from genetic records necessarily makes the information anonymous.

9. Medical Negligence and Professional Liability

Cross-border tele-genetics creates complex questions about the applicable standard of care.

Suppose a foreign laboratory incorrectly identifies a pathogenic genetic variant. A remote counsellor communicates the result, and the patient makes an irreversible reproductive decision.

Potential defendants may include:

The genetic laboratory.

The interpreting geneticist.

The telemedicine platform.

The treating physician.

The sample-collection centre.

The genetic-testing manufacturer.

Possible causes of action include:

Negligence.

Breach of contract.

Professional misconduct.

Defective medical services.

Misrepresentation.

Breach of confidentiality.

Data-protection violations.

The court must examine the actual role of each participant rather than automatically attributing all liability to the platform or laboratory.

Jurisdictional problems

A patient may face several practical difficulties:

The defendant is located overseas.

The contract contains a foreign jurisdiction clause.

The genetic laboratory's insurance does not cover foreign claims.

Evidence is stored in another country.

The foreign court applies a different limitation period.

A judgment must be enforced against assets abroad.

Contractual choice-of-law clauses cannot necessarily override mandatory consumer-protection, privacy or professional-regulation laws.

10. Important Case Laws

There is no comprehensive body of reported judgments specifically deciding the legality of cross-border tele-genetics as a distinct service. The following judgments establish the legal principles that courts and regulators can apply to remote genetic testing, genomic privacy, DNA evidence, medical consent and international data transfers.

A. Indian Case Laws

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Leading constitutional authority

The Supreme Court recognised privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

Legal principles:

Privacy includes informational privacy.

Personal information deserves constitutional protection.

State interference with privacy must satisfy legality, legitimate purpose, proportionality and procedural safeguards.

Individuals have an important interest in controlling the disclosure of personal information.

Application to tele-genetics:

Genetic information can reveal intimate details about a person's biological identity, hereditary conditions and family relationships. Unauthorised disclosure or state access to genomic information may therefore raise constitutional privacy concerns.

2. Selvi v. State of Karnataka (2010) 7 SCC 263

The Supreme Court considered the constitutional implications of involuntary narco-analysis, polygraph examinations and brain electrical activation profile tests.

The Court discussed the protection against compelled testimonial evidence under Article 20(3), as well as personal liberty and mental privacy under Article 21.

Application:

The case is relevant to involuntary genetic testing and the use of biological information in criminal investigations. It supports the distinction between voluntary medical testing and coercive scientific examination.

It does not establish that every compulsory collection of DNA is unconstitutional.

3. Sharda v. Dharmpal (2003) 4 SCC 493

The Supreme Court considered whether a matrimonial court could direct a party to undergo a medical examination.

It recognised that courts have the power to order medical examinations in appropriate circumstances, while emphasising that such power must be exercised judicially.

Application:

A foreign tele-genetics provider cannot assume that a patient is legally required to undergo genetic testing merely because a family member, employer or insurer requests it.

4. Goutam Kundu v. State of West Bengal (1993) 3 SCC 418

The Supreme Court laid down important principles concerning blood tests in paternity disputes.

It cautioned against routinely ordering blood tests and recognised the importance of protecting personal dignity and family relationships.

Application:

Genetic testing undertaken through foreign laboratories can raise similar questions about privacy, paternity, parentage and the rights of children.

The decision is particularly relevant when a tele-genetics platform offers DNA-based parentage testing.

5. Bhabani Prasad Jena v. Convenor Secretary, Orissa State Commission for Women (2010) 8 SCC 633

The Supreme Court held that DNA testing should not be ordered mechanically. Courts must consider whether it is necessary for resolving the dispute and balance competing interests.

Application:

A genetic test should not be treated as legally justified merely because modern technology makes it easy to obtain DNA evidence from another country.

The interests of the child, privacy, dignity and the necessity of testing remain relevant.

6. Suchita Srivastava v. Chandigarh Administration (2009) 9 SCC 1

The Supreme Court recognised reproductive choice as an important dimension of personal liberty under Article 21.

Application:

Tele-genetics services involving hereditary disorders, reproductive risks, prenatal screening and family planning should respect the patient's reproductive autonomy.

A genetic counsellor should provide information without unlawfully coercing reproductive decisions.

7. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

The Supreme Court explained the requirements of valid informed consent in medical treatment.

It emphasised that consent for one medical procedure does not automatically authorise a substantially different procedure.

Application:

Consent to genetic testing does not automatically authorise:

Research use of the sample.

Commercial genetic-data exploitation.

Disclosure to relatives.

Uploading genomic information to unrelated databases.

Further testing outside the agreed scope.

8. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

The Supreme Court examined the principles governing criminal liability for medical negligence.

It discussed the standard of care expected from medical professionals and the distinction between ordinary negligence and gross negligence for criminal liability.

Application:

A geneticist who negligently interprets a genomic report may face professional or civil liability. Criminal liability requires satisfaction of the applicable legal standards and cannot be inferred from every incorrect test result.

B. International Case Laws

9. Schrems II (Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems) (Case C-311/18, 2020)

The Court of Justice of the European Union examined international personal-data transfers from the EU to the United States.

It invalidated the EU-US Privacy Shield and explained the need for effective protection when personal data is transferred to third countries.

Application:

A European tele-genetics provider transferring genomic data to a laboratory outside the European Economic Area must comply with GDPR international-transfer requirements.

Contractual safeguards must be assessed in light of the protection available in the receiving country.

10. Google Spain SL v. Agencia Española de Protección de Datos (Case C-131/12, 2014)

The Court examined data protection and the responsibilities of search-engine operators concerning personal information.

Application:

The case is relevant by analogy to the discoverability and continuing circulation of sensitive genetic information online.

It illustrates the difficulties of controlling personal information once it has been disseminated through digital systems.

11. Lindqvist (Case C-101/01, 2003)

The Court examined the application of European data-protection rules to personal information published on an internet website.

Application:

Genetic reports and identifiable patient information published through international tele-genetics platforms may trigger data-protection obligations even when disclosure occurs electronically.

12. Association for Molecular Pathology v. Myriad Genetics, Inc. (569 U.S. 576, 2013)

The United States Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated.

However, synthetically created complementary DNA may be patent-eligible, subject to the relevant patent-law requirements.

Application:

The decision is relevant to the commercialisation of genomic testing, genetic databases and biotechnology services.

A tele-genetics company cannot assume that naturally occurring human genetic sequences become its exclusive property simply because it has isolated, analysed or stored them.

13. ABC v. St George's Healthcare NHS Trust [2015] EWHC 181 (QB)

The English High Court considered the duty of healthcare professionals concerning disclosure of genetic information to relatives who might face a serious hereditary risk.

The case involved a patient who had Huntington's disease and a family member who sought information relevant to her own health.

Application:

This decision is particularly important for tele-genetics.

It illustrates the conflict between:

The patient's confidentiality.

The medical interests of biological relatives.

The potential harm of nondisclosure.

The professional's duty of care.

A tele-genetics provider should have a clear process for managing clinically significant findings that may affect family members.

Important qualification: These cases are relevant authorities by analogy. They do not collectively establish a dedicated international licensing regime or a universal legal duty for tele-genetics providers to disclose results to relatives.

11. Direct-to-Consumer Genetic Testing and Consumer Protection

Direct-to-consumer genetic testing allows consumers to purchase genetic tests without necessarily obtaining a prior referral from a physician.

A company may offer:

Ancestry analysis.

Carrier screening.

Disease-risk estimates.

Pharmacogenetic reports.

Wellness and lifestyle assessments.

Hereditary cancer-risk reports.

However, a company must distinguish between recreational genetic information and clinically validated medical claims.

Major legal concerns

Misleading advertisements: A company must not exaggerate the predictive accuracy or clinical significance of genetic results.

False reassurance: A negative result for selected variants does not establish that an individual is free from a particular disease.

False positive findings: An incorrectly reported pathogenic variant may cause psychological distress and unnecessary medical interventions.

Consumer consent: The consumer must understand the limitations of the test.

Clinical confirmation: Significant findings may require confirmatory testing in an appropriately qualified clinical laboratory.

Unfair commercial practices: Misrepresentations concerning accuracy, privacy or medical usefulness may trigger consumer-protection liability.

In India, the Consumer Protection Act, 2019, may be relevant where the service constitutes a consumer service and its statutory conditions are satisfied.

12. AI-Based Cross-Border Tele-Genetics

Artificial intelligence is increasingly used for genomic interpretation.

Examples include:

Automated identification of genetic variants.

Prediction of hereditary cancer susceptibility.

AI-assisted prenatal risk assessment.

Detection of rare genetic disorders.

Pharmacogenomic recommendations.

Automated interpretation of whole-genome sequencing.

Predictive assessment of inherited neurological diseases.

This creates additional legal responsibilities.

A. Algorithmic transparency

Patients should receive meaningful information about the nature and limitations of AI-assisted clinical assessments.

B. Human professional supervision

An AI system should not be treated as an independent substitute for legally required professional medical judgment.

C. Algorithmic discrimination

Genetic prediction systems may produce inaccurate results for populations inadequately represented in their training data.

D. Liability

Liability may arise from defective software, negligent professional supervision, misleading marketing or improper clinical deployment.

E. Automated decision-making

Where GDPR applies, Article 22 and related safeguards may become relevant when decisions are based solely on automated processing and produce legal or similarly significant effects.

13. Conflict of Laws and International Jurisdiction

A particularly difficult issue is identifying the law applicable when the patient, counsellor, laboratory and digital platform are located in different countries.

Consider this hypothetical example:

Patient: India.

Genetic counsellor: United Kingdom.

Testing laboratory: United States.

Digital platform: Singapore.

Data-storage provider: Germany.

Five legal jurisdictions may become relevant.

Important conflict-of-law principles

1. Lex loci delicti

The law of the place where the tort occurred may be relevant, subject to the applicable conflict-of-laws rules.

2. Lex contractus

The law governing the contractual relationship may determine contractual rights and obligations.

3. Mandatory local laws

A contractual choice of foreign law cannot necessarily displace mandatory laws of the country where the patient receives the service.

4. Jurisdiction agreements

An exclusive foreign court clause may be subject to scrutiny under consumer-protection rules and applicable private international law.

5. Recognition of foreign judgments

A successful claimant may still have to satisfy the legal requirements for recognition and enforcement in the country where the defendant's assets are situated.

In India, Sections 13 and 44A of the Code of Civil Procedure, 1908, are important in examining the conclusiveness and enforcement of foreign judgments and decrees, subject to their conditions and exceptions.

14. Regulatory Compliance Requirements for Cross-Border Tele-Genetics

A legally compliant tele-genetics business should establish a regulatory framework before accepting patients from foreign jurisdictions.

Recommended contractual arrangements

Cross-border providers should consider three separate agreements:

Patient-service agreement: Defines the clinical service, limitations, fees, consent and complaints procedure.

Laboratory agreement: Establishes testing standards, sample custody, quality assurance, result verification and responsibility for errors.

Data-processing agreement: Defines the purpose of processing, security requirements, international transfers, retention and deletion responsibilities.

These agreements should be consistent with mandatory laws in every relevant jurisdiction.

15. Major Legal Challenges

The following issues remain particularly significant for international tele-genetics.

1. Absence of uniform international licensing: A geneticist licensed in one country may not automatically be entitled to provide clinical services in another.

2. Conflicting privacy standards: Countries differ in their treatment of genetic information, consent and international transfers.

3. Familial genetic privacy: Genetic information about one individual can reveal sensitive information about relatives.

4. Unclear professional liability: Several providers may participate in producing and interpreting a single genetic report.

5. Laboratory accreditation differences: A laboratory's accreditation in its home country does not necessarily establish compliance with another country's requirements.

6. Cross-border sample transportation: Biological material may be subject to separate customs, biosafety and research restrictions.

7. Reproductive autonomy: Prenatal genetic testing can create difficult legal questions involving parental choice, disability rights and sex-selection prohibitions.

8. Commercial ownership disputes: Genetic databases, laboratory discoveries and genomic analysis may generate disputes over intellectual property and contractual rights.

9. AI-generated errors: Incorrect interpretation of variants may lead to serious medical and reproductive consequences.

10. Enforcement difficulties: Patients may struggle to obtain compensation from foreign service providers.

16. Suggestions for Legal and Regulatory Reform

A comprehensive regulatory model for cross-border tele-genetics should include:

Mutual recognition arrangements for qualified genetic counsellors and medical geneticists.

International standards for clinical genetic laboratories.

Standardised informed-consent documentation.

Clear rules governing international DNA sample transportation.

Specific safeguards for genetic and familial privacy.

Transparent procedures for AI-assisted genomic interpretation.

Effective cross-border patient complaint mechanisms.

Mandatory professional indemnity arrangements where appropriate.

International cooperation between genetic-testing regulators.

Special protections for children and reproductive genetic information.

A multilateral agreement could establish minimum standards for genetic-data security, professional accountability, clinical validity and patient remedies without requiring every country to adopt identical medical licensing systems.

17. Important Distinction: Legal Tele-Genetics Versus Illegal Tele-Genetics

The legality of a particular activity depends on its purpose, location, participants and applicable national legislation. Not every direct-to-consumer genetic service is medical practice, and not every international transfer of genetic information is prohibited.

18. Conclusion

Cross-border tele-genetics is an important development in modern healthcare because it allows patients to access genetic expertise and diagnostic services beyond geographical boundaries.

However, its legality cannot be determined solely by examining the country where the genetic laboratory is located.

The patient's location, professional licensing, clinical purpose, genetic-data processing, sample transportation, informed consent and applicable international private law must all be considered.

Indian constitutional jurisprudence, particularly Puttaswamy, Selvi, Sharda, Goutam Kundu and Samira Kohli, provides important foundations for protecting privacy, dignity, reproductive autonomy and informed consent.

International decisions such as Schrems II, Myriad Genetics and ABC v. St George's Healthcare NHS Trust further demonstrate the importance of data-transfer safeguards, genetic information rights and familial confidentiality.

The fundamental legal principle is that technological access to genetic healthcare across national borders must not eliminate the patient's rights to privacy, informed consent, professional medical care and effective legal remedies.

19. Important Legislation and Reference Materials

For academic research and legal examination, the following primary materials are particularly useful:

Useful primary sources:

Government of India – Telemedicine Practice Guidelines, 2020.

Ministry of Health and Family Welfare – Telemedicine Regulations.

US FDA – Direct-to-Consumer Genetic Tests.

Supreme Court of India – DNA testing, privacy and paternity judgment, 2025.

Supreme Court of India – Scientific testing and constitutional rights judgment.

Academic research takeaway: Cross-border tele-genetics should be studied as an intersection of international healthcare regulation, biotechnology law, genetic privacy, medical negligence, reproductive autonomy, data sovereignty and conflict of laws. Its central regulatory challenge is establishing accountability when the patient, professional, laboratory and genomic database are situated in different countries.